SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
TEVA Analysis & Videos »
TEVA: Bull or Bear?
New Stock Indexes to Track Trends in Healthcare Sector
TEVA
|
|
|
+3.70%
in
11 days
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
|
Teva (TEVA): Baby-boomers give boost to generics
TEVA
+1.79%
in
25 days
Filed under: International markets, Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Israel, Obama Picks  "The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.
In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA). <>Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic...
|
Save money, give stock to charity!
TEVA
-7.59%
in
145 days
Filed under: Palm Inc (PALM), Teva Pharm Indus ADR (TEVA), Stocks to Sell  Surviving this recession is foremost on peoples' minds, but giving to charity is especially important in times like these. So how can you effectively give while preserving your net worth? If you plan on liquidating any profitable, or taxable, positions in the stock market thanks to the current uptrend and also want to give to your favorite charity, the strategy outlined below is key to optimizing your gift, as well as your capital. <>Though giving cash to causes is the most popular form of charity, desperate times call f...
|
Teva (TEVA): Generic profits
TEVA
+10.17%
in
140 days
(closed on 10/14/09)
Filed under: International markets, Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy, Obama Picks "Generic drug mak Teva Pharmaceutical, Ltd. (NASDAQ: TEVA) delivered respectable earnings results," says Jack Adamo, who added the stock his Insiders Plus model portfolio. "The company's earnings were up 4% on a proforma non-GAAP basis. In this case, that's the correct measurement. Net GAAP earnings were up tremendously, but aren't really representative of normal business factors. <>"Although Teva gets much of its earnings from its proprietary multiple sclerosis drug, Copaxone, its primary bu...
|
FDA, Clinical Trial Calendar Updates: THRX, GILD, TEVA, ALNY, RNUGF
TEVA
|
|
|
+10.50%
in
205 days
(closed on 10/28/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 112 entries through 4/6/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> The Clinical Trial Calen...
|
Momenta Pharma's Three-Part Strategy
TEVA
|
|
|
+1.69%
in
31 days
(closed on 04/06/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta...
|
Big Pharma Goes Generic
TEVA
|
|
|
-1.84%
in
8 days
(closed on 03/06/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
Caraco Pharma Awaits FDA Inspection in May
TEVA
|
|
|
-0.09%
in
20 hours
(closed on 02/26/09)
By Mike Havrilla on 2/25/09 I spoke with the investor relations representative for Caraco Pharma (CPD) earlier this week and received some clarity on the expected timeline for resolving the major overhang on the stock price related to the FDA warning letter over Form 483 concerns by the agency stemming from quality control issues raised during an inspection of manufacturing facilities last year. <> Caraco has responded in full to the warning letter and the FDA will evaluate the corrective actions taken by the Company at its next s...
|
A 130/30 Pharma Trade
TEVA
|
|
|
-2.89%
in
5 days
(closed on 02/25/09)
By Mike Havrilla on 2/20/09 ETF Innovators The tables at my website link below include 12 U.S. listed companies from the ETF Innovators Global Generic Drug Index along with seven brand drug companies, which are ranked in descending order based on their patent expiration exposure through the end of 2011 as a percentage of total trailing 12-month revenue. <> Investors who are bullish on the generic drug industry may consider implementing a 130/30 pharma trade by shorting any/all...
|
New Website for Healthcare Investors and Traders
TEVA
|
|
|
+9.58%
in
10 days
(closed on 02/20/09)
<> A new website for healthcare investors and traders should be ready to launch by the end of February, which is designed to provide users with more features beyond my current blog format.
The site will feature its own blog, discussion forum, news feeds, videos, stock commentaries (including multiple contributors), and other unique content – including my FDA and Clinical Trial Calendars plus a database that includes hundreds of foreign and U.S.-listed stocks in the healthcare sector which are organized into unique indexes, including:
1....
|
Healthcare Investing Trends in '09 and Beyond
TEVA
|
|
|
+0.78%
in
3 days
(closed on 02/10/09)
<> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector.
Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>...
|
Healthcare Investing Trends in '09 and Beyond
TEVA
|
|
|
+0.00%
in
0 minute
(closed on 02/07/09)
<> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector.
Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>...
|
A New Global Healthcare Composite Index
TEVA
|
|
|
-1.86%
in
25 days
(closed on 02/07/09)
<> 
The accompanying table [click to enlarge] presents the top five rated companies with market caps of at least $100M from each of the eight new ETF Innovators healthcare indexes, including a database exceeding 500 companies worldwide. The Healthcare Composite Index is a dynamic, semi-active index with quarterly rebalancing which consists of the 40 top-rated companies on an equal weight basis from each of the eight global healthcare indexes listed below and represents an alternative strategy to existing health composite ETF...
|
Caraco Pharma: Defensive Growth at a Value Price
TEVA
|
|
|
+1.51%
in
41 days
(closed on 01/13/09)
<> Caraco Pharma (CPD) offers a compelling value at its current price of $3.30 per share and I bought some shares today, as the stock has lost an astounding two-thirds of its market value in just the past month and over three-quarters of value in the past year.
1.) Defensive: Healthcare Sector, Generic Drug Industry
2.) Growth: Net income of $17.9M for the first six months of FY09 (up 36% from the year-ago period) on $230.5M in revenue for the same time period (up 200% from a year ago) – largely due to a distributi<>< />< /><>< />< />< />< />< />< />...
|
People Bullish on TEVA
People Bearish on TEVA
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on TEVA |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Teva Pharmaceutical Industries Ltd
- Answers.com
If you're looking for the most accurate way to predict the direction a stock or the market is headed, 
